255 related articles for article (PubMed ID: 7970942)
41. Abnormal plasma fibrinolysis in patients with rheumatoid arthritis and impaired endothelial fibrinolytic response in those complicated by vasculitis.
Lau CS; McLaren M; Hanslip J; Kerr M; Belch JJ
Ann Rheum Dis; 1993 Sep; 52(9):643-9. PubMed ID: 8239758
[TBL] [Abstract][Full Text] [Related]
42. Fibrinolytic and inflammatory processes in pleural effusions.
Philip-Joët F; Alessi MC; Philip-Joët C; Aillaud M; Barriere JR; Arnaud A; Juhan-Vague I
Eur Respir J; 1995 Aug; 8(8):1352-6. PubMed ID: 7489803
[TBL] [Abstract][Full Text] [Related]
43. Tumor necrosis factor alpha induces endothelial galactosyl transferase activity and verocytotoxin receptors. Role of specific tumor necrosis factor receptors and protein kinase C.
van de Kar NC; Kooistra T; Vermeer M; Lesslauer W; Monnens LA; van Hinsbergh VW
Blood; 1995 Feb; 85(3):734-43. PubMed ID: 7530504
[TBL] [Abstract][Full Text] [Related]
44. Repeated infusions of DDAVP induce low response of FVIII and vWF but not of plasminogen activators.
Vicente V; Estellés A; Laso J; Moraleda JM; Rivera J; Aznar J
Thromb Res; 1993 Apr; 70(2):117-22. PubMed ID: 8322282
[TBL] [Abstract][Full Text] [Related]
45. Fibrinolytic shut-down after surgery: impairment of the balance between tissue-type plasminogen activator and its specific inhibitor.
D'Angelo A; Kluft C; Verheijen JH; Rijken DC; Mozzi E; Mannucci PM
Eur J Clin Invest; 1985 Dec; 15(6):308-12. PubMed ID: 3938400
[TBL] [Abstract][Full Text] [Related]
46. Characterization and fibrinolytic properties of human omental tissue mesothelial cells. Comparison with endothelial cells.
van Hinsbergh VW; Kooistra T; Scheffer MA; Hajo van Bockel J; van Muijen GN
Blood; 1990 Apr; 75(7):1490-7. PubMed ID: 2107884
[TBL] [Abstract][Full Text] [Related]
47. Effects of TNF alpha on verocytotoxin cytotoxicity in purified human glomerular microvascular endothelial cells.
van Setten PA; van Hinsbergh VW; van der Velden TJ; van de Kar NC; Vermeer M; Mahan JD; Assmann KJ; van den Heuvel LP; Monnens LA
Kidney Int; 1997 Apr; 51(4):1245-56. PubMed ID: 9083293
[TBL] [Abstract][Full Text] [Related]
48. Hemostatic and fibrinolytic changes are related to inflammatory conditions in patients with psoriatic arthritis--effect of different treatments.
Di Minno MN; Iervolino S; Peluso R; Di Minno A; Ambrosino P; Scarpa R;
J Rheumatol; 2014 Apr; 41(4):714-22. PubMed ID: 24532831
[TBL] [Abstract][Full Text] [Related]
49. Tissue-type plasminogen activator activity in HIV-associated HUS.
Peraldi MN; Maslo C; Berrou J; Rondeau E; Rozenbaum W; Sraer JD
Nephrol Dial Transplant; 1998 Apr; 13(4):919-23. PubMed ID: 9568850
[TBL] [Abstract][Full Text] [Related]
50. Fibrinolytic responses to 1-desamino-8-D-arginine-vasopressin in patients with congenital nephrogenic diabetes insipidus.
Knoers N; Brommer EJ; Willems H; van Oost BA; Monnens LA
Nephron; 1990; 54(4):322-6. PubMed ID: 2109264
[TBL] [Abstract][Full Text] [Related]
51. Physical activity status and adverse age-related differences in coagulation and fibrinolytic factors in women.
DeSouza CA; Jones PP; Seals DR
Arterioscler Thromb Vasc Biol; 1998 Mar; 18(3):362-8. PubMed ID: 9514404
[TBL] [Abstract][Full Text] [Related]
52. Hemostatic parameters in sepsis patients treated with anti-TNF alpha-monoclonal antibodies.
Salat C; Boekstegers P; Holler E; Werdan K; Reinhardt B; Fateh-Moghadam S; Pihusch R; Kaul M; Beinert T; Hiller E
Shock; 1996 Oct; 6(4):233-7. PubMed ID: 8902937
[TBL] [Abstract][Full Text] [Related]
53. Fibrinogen, t-PA, and PAI-1 plasma levels in patients with pulmonary hypertension.
Huber K; Beckmann R; Frank H; Kneussl M; Mlczoch J; Binder BR
Am J Respir Crit Care Med; 1994 Oct; 150(4):929-33. PubMed ID: 7921465
[TBL] [Abstract][Full Text] [Related]
54. The antithrombotic effect of dextran-40 in man is due to enhanced fibrinolysis in vivo.
Jones CI; Payne DA; Hayes PD; Naylor AR; Bell PR; Thompson MM; Goodall AH
J Vasc Surg; 2008 Sep; 48(3):715-22. PubMed ID: 18572351
[TBL] [Abstract][Full Text] [Related]
55. Development of a Hypercoagulable-Hypofibrinolytic State Early After Spinal Cord Injury.
Park AJ; Garcia VP; Greiner JJ; Berry AR; Cardenas HL; Wegerson KN; Stauffer B; DeSouza CA
Arch Phys Med Rehabil; 2024 May; 105(5):843-849. PubMed ID: 37977547
[TBL] [Abstract][Full Text] [Related]
56. Effect of tumor necrosis factor on the human fibrinolytic system.
Silverman P; Goldsmith GH; Spitzer TR; Rehmus EH; Berger NA
J Clin Oncol; 1990 Mar; 8(3):468-75. PubMed ID: 2106575
[TBL] [Abstract][Full Text] [Related]
57. Fibrinolytic activity in laparoscopic cholecystectomy.
Martinez-Ramos C; Lopez-Pastor A; Núñez-Peña JR; Ruiz-Caravaca ML; Ruiz de Gopegui M; Sanz-López R; Jorgensen TW; Tamames-Escobar S
J Laparoendosc Adv Surg Tech A; 1998 Dec; 8(6):417-23. PubMed ID: 9916595
[TBL] [Abstract][Full Text] [Related]
58. The effect of basal insulin glargine on the fibrinolytic system and von Willebrand factor in people with dysglycaemia and high risk for cardiovascular events: Swedish substudy of the Outcome Reduction with an Initial Glargine Intervention trial.
Rautio A; Boman K; Gerstein HC; Hernestål-Boman J; Lee SF; Olofsson M; Mellbin LG
Diab Vasc Dis Res; 2017 Jul; 14(4):345-352. PubMed ID: 28403644
[TBL] [Abstract][Full Text] [Related]
59. Plasmin generation and fibrin(ogen)olysis following desmopressin infusion.
Takahashi H; Tatewaki W; Wada K; Niwano H; Hanano M; Shibata A
Am J Hematol; 1991 Apr; 36(4):255-8. PubMed ID: 1826408
[TBL] [Abstract][Full Text] [Related]
60. Urokinase-type plasminogen activator release after DDAVP in von Willebrand disease: different behaviour of plasminogen activators according to the synthesis of von Willebrand factor.
Patrassi GM; Sartori MT; Casonato A; Viero ML; Pontara E; Saggiorato G; Girolami A
Thromb Res; 1992 Jun; 66(5):517-26. PubMed ID: 1523608
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
